Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2001): Robinson JB+, Gynecol Oncol 82(3), 550 (with
carboplatin)
(2001): Szebeni J+, Int Immunopharmacol 1(4), 721
(2001): Yamada Y+, Ann Oncol 12(8), 1133 (15%)
(1998): Borovik R+, Harefuah (Hebrew) 134, 605
(1998): Lokich J+, Ann Oncol 9, 573
(1998): Tsavaris NB+, Cancer Chemother Pharmacol 42, 509
(1995): Del Priore G+, Gynecol Oncol 56, 316
(1994): Uziely B+, Ann Oncol 5, 474
(1993): Peereboom DM+, J Clin Oncol 11, 885
Inappropriate secretion of antidiuretic hormone (SIADH)
(2005): Yokoyama Y+, Eur J Gynaecol Oncol 26(5), 531
Infections (sic) (3–22%)
(2006): Yamamoto N+, Anticancer Res 26(1B), 777
(2003): Formenti SC+, J Clin Oncol 21(5), 864 (22%)
(2003): Kuhnt T+, Strahlenther Onkol 179(10), 673
(2002): Souglakos J+, Cancer 95(6), 1326 (3%)
(2001): Fidias P+, Clin Cancer Res 7(12), 3942 (8.8%)
Injection-site cellulitis (>10%)
Injection-site extravasation (>10%)
(2002): Barutca S+, Support Care Cancer 10(7), 563
(1997): Herrington JD+, Pharmacotherapy 17, 163
(1995): Berghmans T+, Support Care Cancer 3, 203
(1995): Raymond E+, Rev Med Interne (French) 16, 141
Injection-site pain (>10%)
Injection-site reactions (sic) (13%)
(2003): Leyland-Jones B+, J Clin Oncol 21(21), 3965 (with
trastuzumab)
Myalgia/Myositis/Myopathy/Myotoxicity (19–60%)
(2006): Izquierdo MA+, Eur J Cancer 42(12), 1789 (with
docetaxel)
(2005): Ansari TN+, J Coll Physicians Surg Pak 15(4), 200
(2003): Garrison JA+, Oncology (Huntingt) 17(2), 271
(2003): Leyland-Jones B+, J Clin Oncol 21(21), 3965 (with
trastuzumab)
(2002): Cantu MG+, J Clin Oncol 20(5), 1232 (19%)
(2002): Hasegawa K+, Gan To Kagaku Ryoho 29(4), 569
(2001): Ishikawa H+, Int J Clin Oncol 6(3), 128
(1999): Markman M+, Gynecol Oncol 72, 100
(1999): Villalona-Calero MA+, J Clin Oncol 17(6), 1915 (with
capecitabine)
(1998): Savarese D+, J Clin Oncol 16, 3918
(1997): Jiang Z+, Chung Hua Chung Liu Tsa Chih (Chinese)
19, 445
Nephrotoxicity
(2006): Ozguroglu M+, Int J Gynecol Cancer 16 Suppl 1, 394
(with carboplatin)
Neurotoxicity
(2006): Bamias A+, BMC Cancer 6, 228 (with carboplatin)
(2006): Bell J+, Gynecol Oncol 102(3), 432 (with carboplatin)
(2006): Green MR+, Ann Oncol 17(8), 1263
(2006): Izquierdo MA+, Eur J Cancer 42(12), 1789 (with
docetaxel)
(2006): Koizumi W+, Anticancer Res 26(5B), 3797
(2006): Lachkar S+, Rev Mal Respir 23(1 Pt 1), 73
(2006): Le T+, Gynecol Oncol 102(1), 49 (15%)
(2006): Markman M+, Gynecol Oncol 101(3), 436 (21%)
(2006): Melli G+, Neurobiol Dis 24(3), 525
(2006): Yamamoto N+, Anticancer Res 26(1B), 777
(2005): Kahl BS+, Cancer Invest 23(1), 13
Pain
(2006): Blum JL+, J Clin Oncol 24(27), 4384 (with capecitabine)
(2003): Emoto T+, Gan To Kagaku Ryoho 30(6), 809
(2003): Formenti SC+, J Clin Oncol 21(5), 864 (17%)
Thrombosis
(2006): Feres F+, Catheter Cardiovasc Interv 68(1), 83 (stent)
Tumor lysis syndrome
(2006): Yahata T+, Gynecol Oncol 103(2), 752
PALIFERMIN
Trade name: Kepivance (Amgen)
Indications: Severe oral mucositis in cancer patients
Category: Keratinocyte growth factor
Half-life: 4.5 hours
Clinically important, potentially hazardous interactions
with: heparin
Reactions
Skin
Edema
(2006): Blazar BR+, Blood 108(9), 3216
Erythema (32%)
(2004): Spielberger R+, NEnglJMed351(25), 2590
Pruritus (35%)
(2004): Spielberger R+, NEnglJMed351(25), 2590
Rash (sic) (62%)
(2006): Blazar BR+, Blood 108(9), 3216
(2006): Keefe D+, Support Care Cancer 14(6), 580
(2004): Spielberger R+, NEnglJMed351(25), 2590
Toxicity (sic)
(2005): Siddiqui MA+, Drugs 65(15), 2139
Mucosal
Gingival hyperplasia/hypertrophy
(2001): Das SJ+, JPeriodontol72(6), 745
Oral mucositis
(2006): Keefe D+, Support Care Cancer 14(6), 580
Tongue edema (17%)
(2004): Spielberger R+, NEnglJMed351(25), 2590
Tongue pigmentation (17%)
Other
Fever (39%)
Infections
(2006): Blazar BR+, Blood 108(9), 3216
Pain (16%)
(2006): Blazar BR+, Blood 108(9), 3216
PALIPERIDONE
Trade name: Invega (Janssen)
Indications: Schizophrenia
Half-life: ~23 hours
Clinically important, potentially hazardous interactions
with: N/A
Note: Paliperidone is the active metabolite of risperidone
Reactions
Skin
Angioedema (tongue)
Edema
Other
Abdominal pain
Anaphylactoid reactions/Anaphylaxis
PALIPERIDONE 413